CSL has been granted a patent for proteins that include antibody antigen binding domains targeting the human granulocyte-colony stimulating factor receptor (hG-CSFR). The patent details a nucleic acid encoding these proteins, which neutralize G-CSF signaling through specific variable regions and complementarity determining regions. GlobalData’s report on CSL gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CSL, Personalized cancer vaccines was a key innovation area identified from patents. CSL's grant share as of July 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody proteins targeting human granulocyte-colony stimulating factor receptor
The granted patent US12071484B2 describes a nucleic acid sequence that encodes a protein with an antigen-binding site specifically targeting the human granulocyte-colony stimulating factor receptor (hG-CSFR). This protein is designed to neutralize granulocyte-colony stimulating factor (G-CSF) signaling, which is significant in various biological processes, including hematopoiesis and immune response. The claims detail the structure of the heavy chain variable region (VH) and light chain variable region (VL) of the antibody, including specific sequences for complementarity determining regions (CDRs) and the potential configurations of the protein, such as single-chain Fv fragments or chimeric forms.
Additionally, the patent outlines methods for producing this protein by expressing the nucleic acid in isolated or recombinant cells, followed by potential isolation and formulation into pharmaceutical compositions. The claims also encompass various combinations of VH and VL sequences, providing a comprehensive framework for developing therapeutic antibodies targeting hG-CSFR. This innovation may have implications for treating conditions related to G-CSF signaling, thereby contributing to advancements in antibody-based therapies.
To know more about GlobalData’s detailed insights on CSL, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
